



## Clinical trial results:

**A Phase IV Open-label, single-arm, single-dose, multicenter study to evaluate the saFEty, toLerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric participants from Latin America with spinal muscular atrophy (SMA) - OFELIA**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2023-000864-67 |
| Trial protocol           | Outside EU/EEA |
| Global end of trial date | 08 August 2023 |

### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 21 February 2024 |
| First version publication date | 21 February 2024 |

### Trial information

#### Trial identification

|                       |               |
|-----------------------|---------------|
| Sponsor protocol code | COAV101A1IC01 |
|-----------------------|---------------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT05073133 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                           |
|------------------------------|-------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Novartis Pharma AG                                                                        |
| Sponsor organisation address | Novartis Campus, Basel, Switzerland,                                                      |
| Public contact               | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com |
| Scientific contact           | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com |

Notes:

### Paediatric regulatory details

|                                                                      |                     |
|----------------------------------------------------------------------|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP)       | Yes                 |
| EMA paediatric investigation plan number(s)                          | EMA-002168-PIP01-17 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No                  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes                 |

Notes:

## Results analysis stage

|                                                      |                |
|------------------------------------------------------|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 08 August 2023 |
| Is this the analysis of the primary completion data? | No             |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 08 August 2023 |
| Was the trial ended prematurely?                     | No             |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to assess the safety and tolerability of OAV101 over an 18-months post-infusion period in participants with SMA weighing  $\leq 17$  kg.

The primary endpoint was to evaluate treatment emergent AEs and SAEs; to evaluate important identified and potential risks and to evaluate changes from baseline in vital signs, cardiac safety assessments, and clinical laboratory results. The secondary endpoint was to evaluate the efficacy of OAV101 at 6-, 12-, and 18-months post-infusion in participants with SMA weighing  $\leq 17$  kg, as measured by Development Motor Milestones according to the World Health Organization Multicentre Growth Reference Study (WHO-MGRS).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 04 November 2021 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |              |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Brazil: 10   |
| Country: Number of subjects enrolled | Argentina: 6 |
| Worldwide total number of subjects   | 16           |
| EEA total number of subjects         | 0            |

Notes:

### Subjects enrolled per age group

|                                           |    |
|-------------------------------------------|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 16 |

|                           |   |
|---------------------------|---|
| Children (2-11 years)     | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years)      | 0 |
| From 65 to 84 years       | 0 |
| 85 years and over         | 0 |

## Subject disposition

### Recruitment

Recruitment details:

16 participants were enrolled into the study, at five sites from Brazil (three sites) and Argentina (two sites). Six participants were from Argentina and 10 from Brazil.

### Pre-assignment

Screening details:

On Day -1, participants were admitted to the hospital for pre-treatment baseline procedures including prednisolone treatment per study protocol.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Not applicable                 |
| Blinding used                | Not blinded                    |

### Arms

|           |        |
|-----------|--------|
| Arm title | OAV101 |
|-----------|--------|

Arm description:

A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes

|                                        |                                               |
|----------------------------------------|-----------------------------------------------|
| Arm type                               | Experimental                                  |
| Investigational medicinal product name | Onasemnogene abeparvovec                      |
| Investigational medicinal product code | OAV101                                        |
| Other name                             | AVXS-101; Zolgensma; Onasemnogene abeparvovec |
| Pharmaceutical forms                   | Solution for infusion                         |
| Routes of administration               | Intravenous use                               |

Dosage and administration details:

1.1e14 vg/kg

|                                       |        |
|---------------------------------------|--------|
| <b>Number of subjects in period 1</b> | OAV101 |
| Started                               | 16     |
| Completed                             | 14     |
| Not completed                         | 2      |
| Adverse event, serious fatal          | 2      |

## Baseline characteristics

### Reporting groups

|                       |        |
|-----------------------|--------|
| Reporting group title | OAV101 |
|-----------------------|--------|

Reporting group description:

A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes

| Reporting group values                                | OAV101 | Total |  |
|-------------------------------------------------------|--------|-------|--|
| Number of subjects                                    | 16     | 16    |  |
| Age categorical                                       |        |       |  |
| Units: Subjects                                       |        |       |  |
| In utero                                              | 0      | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0      | 0     |  |
| Newborns (0-27 days)                                  | 0      | 0     |  |
| Infants and toddlers (28 days-23<br>months)           | 16     | 16    |  |
| Children (2-11 years)                                 | 0      | 0     |  |
| Adolescents (12-17 years)                             | 0      | 0     |  |
| Adults (18-64 years)                                  | 0      | 0     |  |
| From 65-84 years                                      | 0      | 0     |  |
| 85 years and over                                     | 0      | 0     |  |
| Age Continuous                                        |        |       |  |
| Units: months                                         |        |       |  |
| arithmetic mean                                       | 15.79  |       |  |
| standard deviation                                    | ± 5.89 | -     |  |
| Sex: Female, Male                                     |        |       |  |
| Units: Participants                                   |        |       |  |
| Female                                                | 11     | 11    |  |
| Male                                                  | 5      | 5     |  |

## End points

### End points reporting groups

|                                                                    |        |
|--------------------------------------------------------------------|--------|
| Reporting group title                                              | OAV101 |
| Reporting group description:                                       |        |
| A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes |        |

### Primary: Number of Participants with treatment emergent AEs and SAEs

|                 |                                                        |
|-----------------|--------------------------------------------------------|
| End point title | Number of Participants with treatment emergent AEs and |
|-----------------|--------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence (eg any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Changes from baseline in vital signs, cardiac safety assessments, and clinical laboratory results are reported as Adverse Events if clinically significant and as applicable, per investigator assessment.

Disc. = discontinuation

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Month 18

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable for AEs and also not applicable for single arm studies.

| End point values                                 | OAV101          |  |  |  |
|--------------------------------------------------|-----------------|--|--|--|
| Subject group type                               | Reporting group |  |  |  |
| Number of subjects analysed                      | 16              |  |  |  |
| Units: Participants                              |                 |  |  |  |
| Any treatment-emergent adverse events (AEs)      | 16              |  |  |  |
| Any treatment-emergent AEs related to OAV101     | 11              |  |  |  |
| Any serious treatment-emergent adverse events    | 11              |  |  |  |
| Serious treatment-emergent AEs related to OAV101 | 3               |  |  |  |
| Treatment-emergent AEs leading to study disc.    | 0               |  |  |  |
| Treatment-emergent AEs leading to death          | 2               |  |  |  |
| Treatment-emergent AEs of special interest       | 12              |  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Primary: Evaluation of important identified and important potential risks - treatment-emergent adverse events of special interest

|                 |                                                                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Evaluation of important identified and important potential risks - treatment-emergent adverse events of special interest <sup>[2]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence (eg any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Adverse events of special interest (AESI) are defined by the important identified risk and important potential risk: Hepatotoxicity, Thrombocytopenia, Cardiac adverse events, Sensory abnormalities suggestive of ganglionopathy, and Thrombotic microangiopathy. These were assessed by the investigator.

PT = preferred term

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Month 18

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable for AEs and also not applicable for single arm studies.

| End point values                                | OAV101          |  |  |  |
|-------------------------------------------------|-----------------|--|--|--|
| Subject group type                              | Reporting group |  |  |  |
| Number of subjects analysed                     | 16              |  |  |  |
| Units: Participants                             |                 |  |  |  |
| Risk name: Hepatotoxicity                       | 11              |  |  |  |
| -PT: Aspartate aminotransferase increased       | 5               |  |  |  |
| -PT: Alanine aminotransferase increased         | 5               |  |  |  |
| -PT: Blood alkaline phosphatase increased       | 2               |  |  |  |
| -Preferred term: Bilirubin conjugated increased | 2               |  |  |  |
| -PT: Gamma-glutamyltransferase increased        | 5               |  |  |  |
| -Preferred term: Hepatic enzyme increased       | 3               |  |  |  |
| -Preferred term: Hepatic failure                | 1               |  |  |  |
| -Preferred term: Transaminases increased        | 2               |  |  |  |
| Risk name: Thrombocytopenia                     | 5               |  |  |  |
| -Preferred term: Platelet count decreased       | 4               |  |  |  |
| -Preferred term: Thrombocytopenia               | 1               |  |  |  |
| Risk name: Thrombotic microangiopathy           | 2               |  |  |  |
| -Preferred term: Thrombotic microangiopathy     | 2               |  |  |  |

## Statistical analyses

No statistical analyses for this end point

**Secondary: Number of participants who achieve Development Motor Milestones according to the World Health Organization-Multicentre Growth Reference Study (WHO-MGRS)**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of participants who achieve Development Motor Milestones according to the World Health Organization-Multicentre Growth Reference Study (WHO-MGRS) |
| End point description:<br>The World Health Organization-Multicentre Growth Reference Study (WHO-MGRS) was used to measure developmental motor milestones. This was assessed via the milestone checklist. The 6 developmental milestones are: sitting without support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone and walking alone. A yes response indicates that the patient reached a particular development milestone. |                                                                                                                                                          |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary                                                                                                                                                |
| End point timeframe:<br>Baseline (Screening), and at Weeks 26, 52 and 78                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                          |

| End point values                        | OAV101          |  |  |  |
|-----------------------------------------|-----------------|--|--|--|
| Subject group type                      | Reporting group |  |  |  |
| Number of subjects analysed             | 16              |  |  |  |
| Units: Participants                     |                 |  |  |  |
| Screening - Sitting without support     | 6               |  |  |  |
| Screening - Hands-and-knees crawling    | 2               |  |  |  |
| Screening - Standing with assistance    | 1               |  |  |  |
| Screening - Walking with assistance     | 0               |  |  |  |
| Screening - Standing alone              | 0               |  |  |  |
| Screening - Walking alone               | 0               |  |  |  |
| Week 26 Sitting without support (n=14)  | 12              |  |  |  |
| Week 26 Hands-and-knees crawling (n=14) | 2               |  |  |  |
| Week 26 Standing with assistance (n=14) | 2               |  |  |  |
| Week 26 Walking with assistance (n=14)  | 2               |  |  |  |
| Week 26 Standing alone (n=14)           | 1               |  |  |  |
| Week 26 Walking alone (n=14)            | 0               |  |  |  |
| Week 52 Sitting without support (n=13)  | 10              |  |  |  |
| Week 52 Hands-and-knees crawling (n=13) | 4               |  |  |  |
| Week 52 Standing with assistance (n=13) | 7               |  |  |  |
| Week 52 Walking with assistance (n=13)  | 3               |  |  |  |
| Week 52 Standing alone (n=13)           | 6               |  |  |  |
| Week 52 Walking alone (n=13)            | 2               |  |  |  |
| Week 78 Sitting without support (n=12)  | 10              |  |  |  |
| Week 78 Hands-and-knees crawling (n=12) | 3               |  |  |  |
| Week 78 Standing with assistance (n=12) | 7               |  |  |  |
| Week 78 Walking with assistance (n=12)  | 2               |  |  |  |
| Week 78 Standing alone (n=12)           | 3               |  |  |  |
| Week 78 Walking alone (n=12)            | 1               |  |  |  |



## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are reported from the single dose of study treatment plus 18 months post treatment, up to a maximum duration of 18 months.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

### Reporting groups

|                       |          |
|-----------------------|----------|
| Reporting group title | OAV101A1 |
|-----------------------|----------|

Reporting group description:

A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes

| Serious adverse events                               | OAV101A1         |  |  |
|------------------------------------------------------|------------------|--|--|
| Total subjects affected by serious adverse events    |                  |  |  |
| subjects affected / exposed                          | 11 / 16 (68.75%) |  |  |
| number of deaths (all causes)                        | 2                |  |  |
| number of deaths resulting from adverse events       | 1                |  |  |
| Blood and lymphatic system disorders                 |                  |  |  |
| Thrombotic microangiopathy                           |                  |  |  |
| subjects affected / exposed                          | 2 / 16 (12.50%)  |  |  |
| occurrences causally related to treatment / all      | 2 / 2            |  |  |
| deaths causally related to treatment / all           | 1 / 1            |  |  |
| General disorders and administration site conditions |                  |  |  |
| Pyrexia                                              |                  |  |  |
| subjects affected / exposed                          | 1 / 16 (6.25%)   |  |  |
| occurrences causally related to treatment / all      | 1 / 1            |  |  |
| deaths causally related to treatment / all           | 0 / 0            |  |  |
| Gastrointestinal disorders                           |                  |  |  |
| Vomiting                                             |                  |  |  |
| subjects affected / exposed                          | 1 / 16 (6.25%)   |  |  |
| occurrences causally related to treatment / all      | 1 / 1            |  |  |
| deaths causally related to treatment / all           | 0 / 0            |  |  |
| Hepatobiliary disorders                              |                  |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Hepatic failure                                 |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences causally related to treatment / all | 1 / 1           |  |  |
| deaths causally related to treatment / all      | 1 / 1           |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Pneumonia aspiration                            |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Upper respiratory tract congestion              |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Renal and urinary disorders                     |                 |  |  |
| Renal failure                                   |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences causally related to treatment / all | 1 / 1           |  |  |
| deaths causally related to treatment / all      | 1 / 1           |  |  |
| Infections and infestations                     |                 |  |  |
| Bronchiolitis                                   |                 |  |  |
| subjects affected / exposed                     | 3 / 16 (18.75%) |  |  |
| occurrences causally related to treatment / all | 0 / 4           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| COVID-19                                        |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences causally related to treatment / all | 0 / 2           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Gastroenteritis                                 |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Respiratory tract infection                     |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 3 / 16 (18.75%) |  |  |
| occurrences causally related to treatment / all | 0 / 4           |  |  |
| deaths causally related to treatment / all      | 0 / 1           |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | OAV101A1          |  |  |
|-------------------------------------------------------|-------------------|--|--|
| Total subjects affected by non-serious adverse events |                   |  |  |
| subjects affected / exposed                           | 16 / 16 (100.00%) |  |  |
| Investigations                                        |                   |  |  |
| Alanine aminotransferase increased                    |                   |  |  |
| subjects affected / exposed                           | 5 / 16 (31.25%)   |  |  |
| occurrences (all)                                     | 5                 |  |  |
| White blood cell count increased                      |                   |  |  |
| subjects affected / exposed                           | 1 / 16 (6.25%)    |  |  |
| occurrences (all)                                     | 1                 |  |  |
| Transaminases increased                               |                   |  |  |
| subjects affected / exposed                           | 2 / 16 (12.50%)   |  |  |
| occurrences (all)                                     | 3                 |  |  |
| Platelet count decreased                              |                   |  |  |
| subjects affected / exposed                           | 4 / 16 (25.00%)   |  |  |
| occurrences (all)                                     | 4                 |  |  |
| Hepatic enzyme increased                              |                   |  |  |
| subjects affected / exposed                           | 3 / 16 (18.75%)   |  |  |
| occurrences (all)                                     | 3                 |  |  |
| Gamma-glutamyltransferase increased                   |                   |  |  |
| subjects affected / exposed                           | 5 / 16 (31.25%)   |  |  |
| occurrences (all)                                     | 5                 |  |  |
| Blood lactate dehydrogenase increased                 |                   |  |  |
| subjects affected / exposed                           | 2 / 16 (12.50%)   |  |  |
| occurrences (all)                                     | 2                 |  |  |
| Blood alkaline phosphatase increased                  |                   |  |  |
| subjects affected / exposed                           | 2 / 16 (12.50%)   |  |  |
| occurrences (all)                                     | 2                 |  |  |
| Bilirubin conjugated increased                        |                   |  |  |

|                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                              |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Aspartate aminotransferase increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                     | <p>2 / 16 (12.50%)</p> <p>2</p> <p>5 / 16 (31.25%)</p> <p>9</p>                                                              |  |  |
| <p>Injury, poisoning and procedural complications</p> <p>Femur fracture</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                 | <p>1 / 16 (6.25%)</p> <p>1</p>                                                                                               |  |  |
| <p>Blood and lymphatic system disorders</p> <p>Thrombocytopenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                         | <p>1 / 16 (6.25%)</p> <p>1</p>                                                                                               |  |  |
| <p>General disorders and administration site conditions</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                  | <p>7 / 16 (43.75%)</p> <p>14</p>                                                                                             |  |  |
| <p>Immune system disorders</p> <p>Hypersensitivity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>                                                                                                                                                                                                                                                                      | <p>1 / 16 (6.25%)</p> <p>1</p>                                                                                               |  |  |
| <p>Gastrointestinal disorders</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Salivary hypersecretion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> | <p>1 / 16 (6.25%)</p> <p>1</p> <p>7 / 16 (43.75%)</p> <p>8</p> <p>1 / 16 (6.25%)</p> <p>1</p> <p>1 / 16 (6.25%)</p> <p>1</p> |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 3               |  |  |
| Nausea                                          |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Tonsillitis                                     |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Laryngitis                                      |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Cough                                           |                 |  |  |
| subjects affected / exposed                     | 4 / 16 (25.00%) |  |  |
| occurrences (all)                               | 4               |  |  |
| Catarrh                                         |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Upper respiratory tract congestion              |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 5               |  |  |
| Rhinorrhoea                                     |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Skin and subcutaneous tissue disorders          |                 |  |  |
| Subcutaneous emphysema                          |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Rash                                            |                 |  |  |
| subjects affected / exposed                     | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                               | 1               |  |  |
| Psychiatric disorders                           |                 |  |  |
| Irritability                                    |                 |  |  |
| subjects affected / exposed                     | 2 / 16 (12.50%) |  |  |
| occurrences (all)                               | 2               |  |  |
| Infections and infestations                     |                 |  |  |

|                                   |                 |  |  |
|-----------------------------------|-----------------|--|--|
| Viral infection                   |                 |  |  |
| subjects affected / exposed       | 2 / 16 (12.50%) |  |  |
| occurrences (all)                 | 2               |  |  |
| Urinary tract infection           |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 2               |  |  |
| Upper respiratory tract infection |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Rhinitis                          |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Pneumonia bacterial               |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Pneumonia                         |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 3               |  |  |
| Influenza                         |                 |  |  |
| subjects affected / exposed       | 3 / 16 (18.75%) |  |  |
| occurrences (all)                 | 3               |  |  |
| Gastroenteritis                   |                 |  |  |
| subjects affected / exposed       | 2 / 16 (12.50%) |  |  |
| occurrences (all)                 | 2               |  |  |
| Coxsackie viral infection         |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| Conjunctivitis                    |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |
| COVID-19                          |                 |  |  |
| subjects affected / exposed       | 2 / 16 (12.50%) |  |  |
| occurrences (all)                 | 2               |  |  |
| Asymptomatic bacteriuria          |                 |  |  |
| subjects affected / exposed       | 1 / 16 (6.25%)  |  |  |
| occurrences (all)                 | 1               |  |  |

|                                    |                |  |  |
|------------------------------------|----------------|--|--|
| Metabolism and nutrition disorders |                |  |  |
| Hypoglycaemia                      |                |  |  |
| subjects affected / exposed        | 1 / 16 (6.25%) |  |  |
| occurrences (all)                  | 1              |  |  |
| Decreased appetite                 |                |  |  |
| subjects affected / exposed        | 1 / 16 (6.25%) |  |  |
| occurrences (all)                  | 1              |  |  |



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date          | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24 March 2022 | Numbering correction in the Protocol summary section exclusion criteria; Removal of Canada as a participant country; Adjustment of project title considering the removal of Canada; Removal of Murray 's Secretions Severity Rating Scale; Removal of Yale Pharyngeal Severity Rating Scale; Removal of Anti-SMN antibodies in serum assessment as an exploratory objective; Protocol improvements to confirm that the participants may be discharged 12-48 hours after the infusion, based on Investigator judgment; Protocol improvements to confirm that the safety profile of OAV101 is described in the Investigator Brochure (IB) or package insert; Numbering adjustment performed for items 6.1.2 Additional Study Treatment and 6.1.3 Supply of study treatment; Adjustment in the item 8-1 Assessment Schedule – visit window. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported